Drugs / Pralurbactam
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07327619 | Jan 2026 → Jun 2028 expected | bacterial pneumonia | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07089186 | Apr 2025 → Dec 2026 expected | bacterial pneumonia, urinary tract infection | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06633718 | Oct 2024 → May 2027 expected | infectious peritonitis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pralurbactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06633718 ↗ |
| Modality | Small molecule | — CHEMBL5314477 ↗ |